Advisory board member Todd M. Morgan, MD, provides an overview of the use of complete (whole-gland) high-intensity focused ultrasound (HIFU) as a primary treatment for localized prostate cancer.
The guidelines include several departures from past recommendations on the diagnosis, workup, and evaluation of microhematuria.
Approximately 80% of patients with bladder cancer present with non-muscle-invasive disease (NMIBC). Of these, 15 to 25% will eventually develop muscle-invasive bladder cancer, and there are a number of known predictors of progression to invasive disease.
